NCT00856622

A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients

A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 436 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.

Conditions

• Ocular Hypertension
• Glaucoma
• Open-angle Glaucoma

Interventions

Type	Name	Description
DRUG	i. Fixed combination of latanoprost 0.005% and timolol 0.5%	one drop in the morning and placebo in the evening
DRUG	timolol 0.5% ophthalmic solution	one drop in the morning and evening
DRUG	latanoprost 0.005% ophthalmic solution	placebo in the morning and latanoprost .005% in the evening

Timeline

• Start date: 1997-08-01
• Primary completion: 1999-06-01
• Completion: 1999-06-01
• First posted: 2009-03-06
• Last updated: 2021-02-21

Locations

37 sites across 1 country: Germany